The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the study, which involved infants up to 15 months old, and will form the basis of regulatory filing to ...

The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, ...

“Invasive pneumococcal disease and pneumococcal pneumonia remain critical public health challenges worldwide,” said Dr. Paula Annunziato, senior vice president, infectious diseases and ...

"Invasive pneumococcal disease and pneumococcal pneumonia remain critical public health challenges worldwide," said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines ...

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary.

making administration smoother compared to Prevnar 13. PAHO, a regional office for the Americas arm of the World Health Organization, views the importance of large-scale vaccine production and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Results from a Phase II study completed in June 2023 showed that the vaccine had comparable immunogenicity to Prevnar 13, the control vaccine, after primary and booster vaccinations. The study ...

Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...